Figure 5.

ZIKV promotes activation of the type I IFN pathway in GBM cells

(A–C) CT-2A (A) or 456 GSCs and GBM#27 cells (B and C) were treated with ZIKV-GZ01 for the indicated time. Levels of IFN-α and IFN-β were assessed by qRT-PCR (A and B). ELISAs of secreted IFN-β in 456 GSCs and GBM#27 tumors are shown (C). (D) Immunoblot (IB) showing phosphorylation of the indicated proteins in 456 GSCs and GBM#27 cells treated with ZIKV-GZ01 for the indicated time. (E) 456 GSCs and GBM#27 cells were treated with ZIKV-GZ01 for 24 and 48 h. The mRNA levels of the indicated genes were analyzed by qRT-PCR. (F and G) 456 GSCs (F) and CT-2A (G) cells were treated as indicated for 48 h. The mRNA levels of the indicated genes were analyzed by qRT-PCR. Data are presented as means ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, as assayed by unpaired Student’s t test or Welch’s t test.